Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 151

1.

Corrigendum to "Mouse Mesenchymal Progenitor Cells Expressing Adipogenic and Osteogenic Transcription Factors Suppress the Macrophage Inflammatory Response".

Fernandez N, Renna H, McHugh L, Mazalkova K, Crugnola W, Evans JF.

Stem Cells Int. 2019 Apr 1;2019:8428417. doi: 10.1155/2019/8428417. eCollection 2019.

2.

Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.

Himes BE, Obraztsova K, Lian L, Shumyatcher M, Rue R, Atochina-Vasserman EN, Hur SK, Bartolomei MS, Evans JF, Krymskaya VP.

PLoS One. 2018 May 14;13(5):e0197105. doi: 10.1371/journal.pone.0197105. eCollection 2018.

3.

Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).

Rowbottom MW, Bain G, Calderon I, Lasof T, Lonergan D, Lai A, Huang F, Darlington J, Prodanovich P, Santini AM, King CD, Goulet L, Shannon KE, Ma GL, Nguyen K, MacKenna DA, Evans JF, Hutchinson JH.

J Med Chem. 2017 May 25;60(10):4403-4423. doi: 10.1021/acs.jmedchem.7b00345. Epub 2017 May 15.

PMID:
28471663
4.

Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX.

Hutchinson JH, Rowbottom MW, Lonergan D, Darlington J, Prodanovich P, King CD, Evans JF, Bain G.

ACS Med Chem Lett. 2017 Mar 1;8(4):423-427. doi: 10.1021/acsmedchemlett.7b00014. eCollection 2017 Apr 13.

5.

Mouse Mesenchymal Progenitor Cells Expressing Adipogenic and Osteogenic Transcription Factors Suppress the Macrophage Inflammatory Response.

Fernandez N, Renna H, McHugh L, Mazolkova K, Crugnola W, Evans JF.

Stem Cells Int. 2017;2017:5846257. doi: 10.1155/2017/5846257. Epub 2017 Jan 16. Erratum in: Stem Cells Int. 2019 Apr 1;2019:8428417.

6.

Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.

Bain G, Shannon KE, Huang F, Darlington J, Goulet L, Prodanovich P, Ma GL, Santini AM, Stein AJ, Lonergan D, King CD, Calderon I, Lai A, Hutchinson JH, Evans JF.

J Pharmacol Exp Ther. 2017 Jan;360(1):1-13. Epub 2016 Oct 17.

PMID:
27754931
7.

Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).

Sun Y, Zhang W, Evans JF, Floreani A, Zou Z, Nishio Y, Qi R, Leung PS, Bowlus CL, Gershwin ME.

Autoimmun Rev. 2016 Aug;15(8):795-800. doi: 10.1016/j.autrev.2016.03.019. Epub 2016 Mar 24. Review.

PMID:
27019050
8.

Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.

Stein AJ, Bain G, Prodanovich P, Santini AM, Darlington J, Stelzer NM, Sidhu RS, Schaub J, Goulet L, Lonergan D, Calderon I, Evans JF, Hutchinson JH.

Mol Pharmacol. 2015 Dec;88(6):982-92. doi: 10.1124/mol.115.100404. Epub 2015 Sep 14.

PMID:
26371182
9.

Mouse aorta-derived mesenchymal progenitor cells contribute to and enhance the immune response of macrophage cells under inflammatory conditions.

Evans JF, Salvador V, George S, Trevino-Gutierrez C, Nunez C.

Stem Cell Res Ther. 2015 Apr 14;6:56. doi: 10.1186/s13287-015-0071-8.

10.

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, Chopra R.

Cell Signal. 2014 Sep;26(9):2016-29. doi: 10.1016/j.cellsig.2014.05.014. Epub 2014 May 29.

11.

Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.

Bäck M, Powell WS, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE.

Br J Pharmacol. 2014 Aug;171(15):3551-74. doi: 10.1111/bph.12665. Epub 2014 Jul 12. Review.

12.

ACTH promotes chondrogenic nodule formation and induces transient elevations in intracellular calcium in rat bone marrow cell cultures via MC2-R signaling.

Evans JF, Rodriguez S, Ragolia L.

Cell Tissue Res. 2013 May;352(2):413-25. doi: 10.1007/s00441-013-1561-6. Epub 2013 Jan 29.

13.

The lipocalin-type prostaglandin D2 synthase knockout mouse model of insulin resistance and obesity demonstrates early hypothalamic-pituitary-adrenal axis hyperactivity.

Evans JF, Islam S, Urade Y, Eguchi N, Ragolia L.

J Endocrinol. 2013 Jan 18;216(2):169-80. doi: 10.1530/JOE-12-0275. Print 2013 Feb.

PMID:
23151358
15.

Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD.

Zhu J, Bandi V, Qiu S, Figueroa DJ, Evans JF, Barnes N, Guntupalli KK, Jeffery PK.

Chest. 2012 Aug;142(2):347-357. doi: 10.1378/chest.11-1581.

16.

Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.

Bain G, King CD, Schaab K, Rewolinski M, Norris V, Ambery C, Bentley J, Yamada M, Santini AM, van de Wetering de Rooij J, Stock N, Zunic J, Hutchinson JH, Evans JF.

Br J Clin Pharmacol. 2013 Mar;75(3):779-90. doi: 10.1111/j.1365-2125.2012.04386.x.

17.

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R.

Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3. Erratum in: Leukemia. 2012 Nov;26(11):2445.

18.

Functional melanocortin-2 receptors are expressed by mouse aorta-derived mesenchymal progenitor cells.

Evans JF, Fernando A, Ragolia L.

Mol Cell Endocrinol. 2012 May 15;355(1):60-70. doi: 10.1016/j.mce.2012.01.019. Epub 2012 Jan 27.

19.

Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2.

Bain G, King CD, Brittain J, Hartung JP, Dearmond I, Stearns B, Truong YP, Hutchinson JH, Evans JF, Holme K.

J Clin Pharmacol. 2012 Oct;52(10):1482-93. Epub 2011 Nov 22.

PMID:
22110163
20.

5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.

Stock NS, Bain G, Zunic J, Li Y, Ziff J, Roppe J, Santini A, Darlington J, Prodanovich P, King CD, Baccei C, Lee C, Rong H, Chapman C, Broadhead A, Lorrain D, Correa L, Hutchinson JH, Evans JF, Prasit P.

J Med Chem. 2011 Dec 8;54(23):8013-29. doi: 10.1021/jm2008369. Epub 2011 Nov 7.

PMID:
22059882

Supplemental Content

Loading ...
Support Center